PLACEBO-CONTROLLED TRIAL OF THE EFFECTS OF GUAR GUM AND METFORMIN ON FASTING BLOOD-GLUCOSE AND SERUM-LIPIDS IN OBESE, TYPE-2 DIABETIC-PATIENTS

被引：70

作者：

LALOR, BC ^{[1
]}

BHATNAGAR, D ^{[1
]}

WINOCOUR, PH ^{[1
]}

ISHOLA, M ^{[1
]}

ARROL, S ^{[1
]}

BRADING, M ^{[1
]}

DURRINGTON, PN ^{[1
]}

机构：

[1] UNIV MANCHESTER,MANCHESTER ROYAL INFIRM,DEPT MED,OXFORD RD,MANCHESTER M13 9WL,LANCS,ENGLAND

来源：

DIABETIC MEDICINE | 1990年 / 7卷 / 03期

关键词：

Guar gum; Metformin; Serum lipids; Serum lipoproteins; Type; 2; diabetes;

D O I：

10.1111/j.1464-5491.1990.tb01378.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Nineteen obese patients with Type 2 diabetes mellitus were treated for periods of 3 months with placebo, guar gum (5 g three times daily) and metformin (500 mg three times daily) in a randomized double‐blind, double‐placebo, cross‐over study. Both active agents decreased fasting blood glucose from 11.4 ± 3.7 mmol l−1 (mean ± SD) to 8.6 ± 2.8 mmol l−1 on metformin (p<0.001) and to 9.5 ± 3.9 mmol l−1 on guar gum (p<0.01). Metformin significantly reduced the very low density lipoprotein (VLDL) cholesterol concentration from 0.62 (+ 0.73, − 0.34) mmol l−1 (geometric mean (+ SD, ‐ SD)) to 0.43 (+ 0.58, − 0.25) mmol l−1, (p<0.02), but unless hyperlipidaemia was present there were no changes in other serum lipid or lipoprotein levels. In patients with serum cholesterol > 6.5 mmol l−1 decreases in serum triglycerides from 3.29 (+ 3.27, − 1.64) to 2.46 (+ 2.55, − 1.25) mmol l−1 (p<0.02) occurred with metformin. In these patients guar gum produced a reduction in serum cholesterol (from 7.70 ± 0.90 to 6.41 ± 1.11 mmol l−1, p<0.01) due to an effect on low density lipoproteins. These differential effects may be important in planning therapy when hyperlipidaemia accompanies Type 2 diabetes. 1990 Diabetes UK

引用

页码：242 / 245

页数：4

共 22 条

[1]

Strategies for the prevention of coronary heart disease: a policy statement of the European Atherosclerosis Society, Eur Heart J, 8, pp. 77-88, (1987)

[2]

Shepherd J., Betteridge DJ, Durrington PN, Et al., Strategies for reducing coronary heart disease and desirable limits for blood lipid concentrations: guidelines of the British Hyperlipidaemia Association, Br Med J, 295, pp. 1245-1246, (1987)

[3]

Report of the National Cholesterol Screening and Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults, Arch Intern Med, 148, pp. 36-39, (1988)

[4]

Sirtori CR, Franceschini G., Gianfranceschi G., Et al., Metformin improves peripheral vascular flow in non hyperlipidaemic patients with arterial disease, J Cardiovasc Pharmacol, 6, pp. 914-923, (1984)

[5]

Fuessl HS, Williams G., Adrian TE, Bloom SR., Guar sprinkled on food: effect on glycaemic control, plasma lipids and gut hormones in non‐insulin dependent diabetic patients, Diabetic Med, 4, pp. 463-468, (1987)

[6]

Calvert GD, Graham JJ, Mannik T., Et al., Effects of therapy on plasma high density lipoprotein cholesterol concentration in diabetes mellitus, Lancet, 2, pp. 66-68, (1978)

[7]

Lisch HT, Sailor S., Lipoprotein patterns in diet, sulphonylurea and insulin treated diabetics, Diabetologia, 20, pp. 118-122, (1981)

[8]

Havel RJ, Eder HA, Bragdon SH., The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum, J Clin Invest, 34, pp. 1345-1353, (1955)

[9]

Durrington PN, Whicher JT, Warren C., Et al., A comparison of methods for the immunoassay of apolipoprotein B in man, Clin Chim Acta, 71, pp. 95-108, (1976)

[10]

Winer BJ., Single‐factor experiments having repeated measures on the same elements, Statistical Principles in Experimental Design, pp. 261-308, (1971)

← 1 2 3 →